New GLP analogue launched

[Raptor]

New GLP analogue launched

Liraglutide (Victoza®) has been launched for the treatment of patients with type 2 diabetes. This new drug is a glucagon-like peptide (GLP-1) analogue and is in the same class as exenatide (Byetta®).

There are slight differences between the two products in terms of the product licence. Exenatide is licensed for combination use with metformin and/or a sulphonylurea in patient not achieving adequate glycaemic control. Liraglutide is licensed in these same combinations and also in combination with metformin and a glitazone.


Δεν είναι ορατοί οι σύνδεσμοι (links). Εγγραφή ή Είσοδος

[Δ. Κουναλάκης]

Παλαιά είδηση Raptor Δες και την φιλολογία σχετικά:
Δεν είναι ορατοί οι σύνδεσμοι (links). Εγγραφή ή Είσοδος

[Raptor]

  Πολύ ενδιαφερον το συγκεκριμενο blog, δεν το είχα υποψη μου.